Know Cancer

forgot password

Phase I/II Trial of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Androgen-Independent Prostate Cancer

Phase 1/Phase 2
Open (Enrolling)
Prostatic Neoplasms

Thank you

Trial Information

Phase I/II Trial of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Androgen-Independent Prostate Cancer

The principal objective of this trial is to evaluate the safety, feasibility, and anti-tumor
effects of a novel bone-targeted regimen consisting of Samarium Sm-153 lexidronam combined
with docetaxel and prednisone. This present study design permits evaluation of the clinical
activity of combining two distinct agents that have shown benefit for the treatment of
patients with advanced androgen-independent prostate cancer and bone metastases. It enables
assessment of potential synergistic interactions between a cytotoxic chemotherapy agent and
a bone-targeting radioisotope agent in the setting of a bone-targeted therapy.

Inclusion Criteria:

- Have histological evidence of adenocarcinoma of the prostate.

- Have progressive castrate metastatic disease.

- Castrate levels of testosterone (<50 ng/ml). Treatment to maintain castrate levels
of testosterone must be continued.

- Must have evidence of at least 3 bone metastases on bone scan.

- Patients for whom initial hormone treatment (exclusive of neoadjuvant hormone
therapy) was a combined androgen blockade approach, must show progression of disease
following withdrawal of the anti-androgen prior to enrollment.

- Patients undergoing prior bisphosphonate treatments are eligible.

- Patients who have received one prior treatment with 153Sm lexidronam or 89Sr are
eligible provided it is at least 12 weeks from treatment with 153Sm lexidronam or 24
weeks from treatment with 89Sr.

- Life expectancy of at least 12 weeks (based on co-morbidity).

- KPS>60.

- Lab requirements:

- White Blood Count (WBC) ≥ 3,000/mm3;

- Absolute Neutrophil Count (ANC) ≥ 1,500/ mm3;

- Platelet (PLT) ≥ 100,000/mm3;

- Hemoglobin (HGB) ≥ 10 mg/dl;

- Bilirubin ≤ 2.0 mg/dl;

- ALT/AST≤ 3 times the upper limit of normal;

- Serum creatinine ≤ 2.0 mg/dl.

- Patients must sign an informed consent.

Exclusion Criteria:

- Patients with small cell carcinoma.

- Patients with predominant visceral metastases (>3 lung or liver lesions) or
symptomatic lymphadenopathy (scrotal or pedal edema).

- Patients who have received more than one course of external beam radiation therapy
directed at bone lesions.

- Clinically significant cardiac disease (New York Heart Association Class III/IV).

- History of other malignancies (other than non-melanoma skin cancer), unless in
complete remission or off therapy for that disease for at least five years.

- Have or are participating in a research study protocol or clinical trial protocol
within 30 days of the date of the baseline visit.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Primary outcome is safety and tolerability of the combination treatment

Principal Investigator

Michael J Morris, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

July 2005

Completion Date:

June 2008

Related Keywords:

  • Prostatic Neoplasms
  • prostate cancer
  • Neoplasms
  • Prostatic Neoplasms



Memorial Sloan-Kettering Cancer Center New York, New York  10021